SERUM PROTEOMIC PROFILING REVEALS THAT THE FATTY ACID SYNTHASE (FASN) INHIBITOR DENIFANSTAT PROVIDES METABOLIC BENEFITS VIA INCREASING FIBROBLAST GROWTH FACTOR 19 (FGF-19) AND DECREASING 3-HYDROXY-3-METHYLGLUTARYL-COA SYNTHASE 1 (HMGCS1) IN NASH PATIENTS

被引：0

作者：

Tsai, Wen-Wei ^{[1
]}

Grimmer, Katharine ^{[1
]}

Zetter, Alithea ^{[1
]}

Beckwith, William ^{[2
]}

Whitley, Penn ^{[3
]}

Martins, Eduardo Bruno ^{[1
]}

Kemble, George ^{[1
]}

Harrison, Stephen A. ^{[4
]}

Loomba, Rohit ^{[5
]}

O'Farrell, Marie ^{[1
]}

机构：

[1] Sagimet Biosciences Inc, San Mateo, CA USA

[2] Somal Operating Co Inc, Boulder, CO USA

[3] Boulder Bioconsulting Inc, Boulder, CO USA

[4] Pinnacle Clin Res, San Antonio, TX USA

[5] Univ Calif San Diego, Div Gastroenterol, Dept Med, NAFLD Res Ctr, La Jolla, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

5054

引用

页码：E162 / E163

页数：2